Cardiol Therapeutics Inc T.CRDL

Alternate Symbol(s): CRDL

Healthcare

Cardiol Therapeutics Inc. is a clinical-stage life sciences company. The Company is focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. It is also developing CRD-38, a novel subcutaneously administered drug intended for use in heart failure. It has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart.

TSX:CRDL - Post by User

Cardiol Therapeutics Inc

<< Previous

Bullboard Posts

Next >>

Post by Lontermon Dec 10, 2020 9:20am

165 Views

Post# 32075593

Logical Question

News on Phase 1 Myocarditis is imminnet in the CEO words- difference between last Renmark Dec 9 to next one is 6 days- I am betting my bottom $$ that the trial results are announced between now to Dec 15 and then potentially initiation of Phase 2/3 in January 2021 with uplist discussion in a couple of months thereafter.

With the trial results for Phase 1 there could be a pop if the results show safety and protection.

what else would be the reason for the conference to be so close to each other

<< Previous

Bullboard Posts

Next >>

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity